CD82 / KAI-1 Antikörper (Antigen Affinität reinigt)

11.02.2012

Produkt-Information von CD82 / KAI-1 Antikörper

Immunogen	Recombinant Human CD82 / KAI-1 protein (Catalog#12275-H08H)
Antibody Type	Rabbit Polyclonal Antibody ( Antibody Purification Platform )
Ig Type	Rabbit IgG
Formulation	0.2 μm filtered solution in PBS with 5% trehalose

CD82 / KAI-1 Antikörper Usage Guide

Specificity	Human CD82 / KAI-1
Western blot	This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human CD82 in WB. Using a DAB detection system, the detection limit for Human CD82 is approximately 1 ng/lane under non-reducing conditions and 4 ng/lane under reducing conditions.
Direct ELISA	This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human CD82. The detection limit for Human CD82 is approximately 0.00245 ng/well.
Storage	This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free. Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

Verwandte Produkte & Themen von CD82 / KAI-1 Antikörper

Verwandte Bereiche:

Proteine:

Antibkörper:

Hintergrund von CD82 / KAI-1 Antikörper

The transmembrane glycoprotein CD82, also known as Kangai (KAI)-1, is a member of the tetraspanin protein family and is a metastasis suppressor implicated in biological processes ranging from fusion, adhesion and migration to apoptosis and cell-morphology alterations. KAI1/CD82 is a candidate metastasis suppressor gene and has been indicated in the disease progression of certain solid tumours. KAI1 plays an important role in cell adhesion, invasion and migration of breast cancer cells, in vitro, and is a potential metastasis suppressor gene in breast cancer. The present study was designed to investigate the expression pattern of KAI-1 in the normal endometrium and uterine tumors and to correlate it with the expression of tumor suppressor protein p53. KAI-1 and p53 show inverse expression. The reduced KAI-1 expression may be the result of dysregulated p53 function and could be an important step in the endometrial carcinogenesis. The loss of KAI1/CD82 expression in invasive and metastatic cancers is due to a complex, epigenetic mechanism that probably involves transcription factors such as NFkappaB, p53, and beta-catenin. Thus, CD82 may be a therapeutic approach for the treatment of a variety of metastatic cancers.

References

Tonoli H. et al., 2005, Trends Mol Med. 11 (12): 563-70.
Kim B. et al., 2010, Biochem Biophys Res Commun. 393 (1): 179-84.
Briese J. et al., 2008, Virchows Arch. 453 (1): 89-96.
Liu WM. et al., 2006, Cancer Lett. 240 (2): 183-94.

Sino Biological Inc. liefert CD82 / KAI-1 Antikörper (Antigen Affinität reinigt) mit höherer Qualität und günstiger Kosten im Vergleich mit anderen globalen Lieferanten.

Weitere Informationen über CD82 / KAI-1 Antikörper (Antigen Affinität reinigt) lesen Sie bitte: http://www.sinobiological.com/goods.php?id=7581